BioCytics Secures G-Rex Grant to Enhance Cancer Treatment Technology

BioCytics Awarded G-Rex Grant from ScaleReady

In a significant milestone for cancer research, BioCytics has officially announced that it has been awarded a $100,000 G-Rex grant from ScaleReady. This vital funding aims to support BioCytics in advancing its innovative cell-based therapy designed to treat solid tumors through the development and optimization of a cGMP G-Rex-based manufacturing process.

The G-Rex grant program, part of a larger initiative by ScaleReady offering $20 million in total funding for Cell and Gene Therapy (CGT) advancements, is tailored to provide substantial support for improving cell manufacturing processes. For BioCytics, this grant is more than just funding; it will significantly expedite the development of their IND-bound immune fraction BCyIF1, which has been crafted specifically to combat solid tumors. Dr. Renaud Warin, BioCytics' Chief Scientific Officer, expressed optimism about the grant's potential impact, emphasizing that it will facilitate access to ScaleReady's array of products and the expertise of their partners, allowing them to harness an extraordinary knowledge base in cell therapy.

BioCytics, founded in 2005, is a health technology company located in Huntersville, North Carolina, sharing space with the Carolina BioOncology Institute. The company employs Autologous Adaptive Cell Therapy (AACT), a cutting-edge approach using a patient's own immune cells to develop an effective immuno-oncology platform aimed at treating various solid tumors. This point-of-care process stands out for its ability to produce non-genetically modified effector cell fractions applicable to all stages of solid tumor conditions.

Commenting on the grant, Josh Ludwig, ScaleReady's Commercial Director, highlighted ScaleReady's commitment to breaking away from traditional business models, emphasizing their enthusiasm for advancing BioCytics' mission. The goal is clear: to offer patients novel and affordable immune cell therapies straight from the Point-of-Care manufacturing setup.

The collaboration strengthens the framework in which BioCytics operates, presenting a synergistic relationship that allows for enhanced research and development opportunities. With the financial backing from ScaleReady, BioCytics is poised to drive their innovative solutions forward, ensuring they can bring transformative therapies to market more efficiently.

ScaleReady is renowned in the CGT sector for its G-Rex-centric manufacturing platforms, catering to a diverse array of organizations. Currently, these solutions are instrumental in about half of all CGT clinical trials and have played vital roles in the development of five commercially approved CGT drugs. The scalability and efficiency of this platform stand to significantly reduce both timelines and costs tied to CGT commercialization.

As BioCytics advances their research and manufacturing capabilities, the overarching aim remains clear: to foster the development of effective cancer therapies that improve patient outcomes. The company is continuously innovating to ensure that their treatments reflect the latest scientific advancements.

For more detailed information on BioCytics and their endeavors in immuno-oncology, you can visit their official website at Biocytics.com or connect with them through LinkedIn. As they embark on this new chapter bolstered by the G-Rex grant, the future of cancer treatment appears brighter with the promise of innovative, patient-centered therapies on the horizon.